OncoPLEX

Search documents
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
Globenewswire· 2025-07-15 12:00
Core Viewpoint - PolyPid Ltd. has introduced a long-acting GLP-1 receptor agonists delivery platform that aims to provide subcutaneous release of GLP-1 for approximately 60 days, significantly extending the duration compared to current weekly injection regimens, which could transform patient care in diabetes and weight management markets [2][3]. Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which allows for controlled, prolonged-release therapeutics [4]. - The company is preparing for a New Drug Application (NDA) submission for its lead product candidate, D-PLEX100, aimed at preventing abdominal colorectal surgical site infections, expected in early 2026 [4]. Product and Technology - The new GLP-1 delivery platform utilizes a polymer-lipid based matrix that enables linear drug release, overcoming the burst release associated with current weekly delivered molecules [2][3]. - This technology has been clinically validated in over 1,000 patients, including two Phase 3 trials, with no major safety concerns reported [3]. Market Potential - The market for GLP-1 therapies is projected to reach $100 billion by 2030, driven by increasing demand in diabetes and obesity treatment [2][9]. - The introduction of the long-acting GLP-1 delivery platform could significantly expand PolyPid's offerings in this growing market [2][3].
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
Globenewswire· 2025-06-16 23:20
Core Viewpoint - PolyPid Ltd. has secured additional funding of $26.7 million through the exercise of warrants, extending its financial runway beyond the anticipated FDA approval of its lead product candidate, D-PLEX₁₀₀ [1][4]. Funding Details - The funding was obtained through new agreements with existing warrant holders for the immediate exercise of warrants to purchase up to 7,626,514 ordinary shares at a price of $3.50 per share [2]. - In exchange for the immediate cash exercise of the warrants, PolyPid will issue new unregistered warrants for the purchase of an equal number of ordinary shares at an exercise price of $4.50 per share, valid for two years [3]. Use of Proceeds - The net proceeds from this funding will be utilized for new drug application (NDA) submission, launch preparations, working capital, and general corporate purposes [4]. Product Information - D-PLEX₁₀₀ is designed to provide prolonged and controlled antibacterial activity at surgical sites to prevent surgical site infections (SSIs) and has received Breakthrough Therapy designation from the FDA [7]. - The product demonstrated a statistically significant reduction in SSIs in the Phase 3 SHIELD II trial, meeting all primary and key secondary endpoints [8][9].
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
Globenewswire· 2025-06-06 20:05
Group 1 - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative therapeutics [4] - The company will host a conference call on June 9, 2025, to report topline data from the SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery [1][2] - D-PLEX100 is currently in Phase 3 clinical trials, while PolyPid is also testing OncoPLEX for solid tumors, starting with glioblastoma [4] Group 2 - The conference call is scheduled for 8:30 AM Eastern Time, and participants are encouraged to register at least 5 minutes prior to the call [2][3] - PolyPid's proprietary PLEX technology allows for controlled, prolonged-release of drugs, enhancing the delivery of Active Pharmaceutical Ingredients [4]
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
Globenewswire· 2025-05-20 11:00
Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative therapeutics [4] - The company utilizes its proprietary PLEX technology for controlled, prolonged-release of drugs, enabling precise delivery over several days to months [4] - PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [4] Upcoming Events - PolyPid will participate in the Lytham Partners Spring 2025 Investor Conference, with a webcast presentation scheduled for May 29, 2025, at 10:15 a.m. ET [2] - The webcast will be accessible via the conference homepage and will be available for replay after the event [2] - Management will also engage in virtual one-on-one meetings with investors during the conference [3]
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
Globenewswire· 2025-04-29 11:00
Core Viewpoint - PolyPid Ltd. is set to report its first quarter 2025 financial results and operational highlights on May 14, 2025, with a conference call scheduled for 8:30 AM Eastern Time to discuss these results and provide business updates [1]. Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which allows for controlled, prolonged-release of therapeutics [4]. - The lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [4]. - The company is also in preclinical stages testing OncoPLEX for treating solid tumors, starting with glioblastoma [4]. Conference Call Details - The conference call will take place on May 14, 2025, at 8:30 AM Eastern Time, and participants are encouraged to register at least 5 minutes prior to the call [2][3]. - For those not asking questions, listening via the webcast is recommended [2].